Avalo Therapeutics Inc. is a clinical-stage precision medicine company which discovers, develops and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology and rare genetic diseases. Avalo Therapeutics Inc., formerly known as Cerecor, is based in WAYNE, Pa.
Revenue (Most Recent Fiscal Year) | $1.92M |
Net Income (Most Recent Fiscal Year) | $-31.54M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 8.05 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.64 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -1638.77% |
Net Margin (Trailing 12 Months) | -1639.50% |
Return on Equity (Trailing 12 Months) | -1439.87% |
Return on Assets (Trailing 12 Months) | -113.95% |
Current Ratio (Most Recent Fiscal Quarter) | 1.82 |
Quick Ratio (Most Recent Fiscal Quarter) | 1.82 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | 138.81 |
Book Value per Share (Most Recent Fiscal Quarter) | $9.11 |
Earnings per Share (Most Recent Fiscal Quarter) | -- |
Earnings per Share (Most Recent Fiscal Year) | $-114.00 |
Diluted Earnings per Share (Trailing 12 Months) | $-616.67 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 1.03M |
Free Float | 1.03M |
Market Capitalization | $15.49M |
Average Volume (Last 20 Days) | 0.30M |
Beta (Past 60 Months) | 1.15 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 0.20% |
Percentage Held By Institutions (Latest 13F Reports) | 87.06% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |